69.36
Ani Pharmaceuticals Inc stock is traded at $69.36, with a volume of 279.14K.
It is up +1.97% in the last 24 hours and up +12.07% over the past month.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
See More
Previous Close:
$68.02
Open:
$67.01
24h Volume:
279.14K
Relative Volume:
1.12
Market Cap:
$1.45B
Revenue:
$486.82M
Net Income/Loss:
$18.78M
P/E Ratio:
84.59
EPS:
0.82
Net Cash Flow:
$100.45M
1W Performance:
+3.26%
1M Performance:
+12.07%
6M Performance:
+20.63%
1Y Performance:
+3.96%
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Name
Ani Pharmaceuticals Inc
Sector
Phone
(218) 634-3500
Address
210 MAIN STREET WEST, BAUDETTE, MN
Compare ANIP with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ANIP
Ani Pharmaceuticals Inc
|
69.36 | 1.45B | 486.82M | 18.78M | 100.45M | 0.82 |
![]()
ZTS
Zoetis Inc
|
163.50 | 72.50B | 9.26B | 2.49B | 2.30B | 5.47 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.98 | 47.08B | 30.25B | 1.37B | 5.08B | 0.4257 |
![]()
HLN
Haleon Plc Adr
|
10.16 | 45.99B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.29 | 17.52B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
312.26 | 13.78B | 2.76B | 1.11B | 898.10M | 22.77 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-14-25 | Initiated | Jefferies | Buy |
Mar-12-25 | Initiated | JP Morgan | Overweight |
Dec-11-24 | Initiated | Leerink Partners | Outperform |
Oct-11-24 | Initiated | Piper Sandler | Overweight |
Mar-15-24 | Initiated | CapitalOne | Overweight |
Aug-22-23 | Reiterated | H.C. Wainwright | Buy |
Mar-01-23 | Initiated | Guggenheim | Buy |
Sep-07-22 | Initiated | H.C. Wainwright | Buy |
Nov-02-21 | Initiated | Truist | Buy |
May-07-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Sep-12-19 | Initiated | Guggenheim | Buy |
May-10-19 | Downgrade | Raymond James | Strong Buy → Outperform |
Oct-16-17 | Reiterated | Canaccord Genuity | Buy |
Jul-31-17 | Initiated | Canaccord Genuity | Buy |
Feb-22-17 | Downgrade | ROTH Capital | Buy → Neutral |
Jun-23-16 | Initiated | Raymond James | Strong Buy |
May-24-16 | Downgrade | Standpoint Research | Buy → Hold |
Nov-13-15 | Initiated | Standpoint Research | Buy |
Sep-28-15 | Upgrade | ROTH Capital | Neutral → Buy |
Aug-05-15 | Reiterated | Oppenheimer | Outperform |
Aug-04-15 | Reiterated | ROTH Capital | Neutral |
Jul-31-15 | Reiterated | Oppenheimer | Outperform |
Jul-15-15 | Reiterated | ROTH Capital | Neutral |
Jun-23-15 | Reiterated | Oppenheimer | Outperform |
May-18-15 | Reiterated | ROTH Capital | Neutral |
May-06-15 | Reiterated | Oppenheimer | Outperform |
Apr-10-15 | Downgrade | ROTH Capital | Buy → Neutral |
Feb-26-15 | Reiterated | ROTH Capital | Buy |
Feb-18-15 | Reiterated | Oppenheimer | Outperform |
View All
Ani Pharmaceuticals Inc Stock (ANIP) Latest News
Zacks.com featured highlights include HIS, ANI Pharmaceuticals, Pediatrix Medical, Fresenius Medical Care and LendingTree - TradingView
ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference - GlobeNewswire
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Fly 25% But Investors Aren't Buying For Growth - simplywall.st
5 Top-Ranked Mid-Cap Stocks to Buy for a Stellar Portfolio - Yahoo Finance
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
Should You Buy ANI Pharmaceuticals (ANIP) After Golden Cross? - Zacks Investment Research
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN
ANI Pharmaceuticals Launches Kionex Suspension For Electrolyte Imbalance Management: Key Trend Transforming... - WhaTech
ANI Pharmaceuticals launches generic Nitazoxanide Tablets By Investing.com - Investing.com South Africa
Ani Pharmaceuticals Launches Nitazoxanide Tablets for Treating Diarrhea -March 19, 2025 at 09:33 am EDT - MarketScreener
ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets - GlobeNewswire
ANI Pharmaceuticals launches generic Nitazoxanide Tablets - Investing.com
ANI Pharmaceuticals Announces The Launch Of Nitazoxanide Tablets -March 19, 2025 at 06:51 am EDT - Marketscreener.com
Generic Drug Alert: ANI Pharmaceuticals Takes On $36M Market With New Alinia Alternative - StockTitan
ANI Pharmaceuticals settles royalty obligation for $17.25 million By Investing.com - Investing.com Australia
ANI Pharmaceuticals Eliminates Royalty Obligation On ILUVIEN And YUTIQ - Nasdaq
ANI Pharmaceuticals settles royalty obligation for $17.25 million - Investing.com India
ANI Pharma buys Iluvien and Yutiq royalties (ANIP:NASDAQ) - Seeking Alpha
ANI Pharma buys royalties linked to Iluvien and Yutiq - MSN
ANI Pharmaceuticals Completes Buyout of Royalty Obligation for Iluvien, Yutiq -March 18, 2025 at 08:20 am EDT - Marketscreener.com
ANI Pharmaceuticals Completes $17.25 Million Buyout of Royalty Obligation for ILUVIEN and YUTIQ - Nasdaq
ANI Pharmaceuticals Announces Buyout Of Royalty Obligation For Iluvien And Yutiq -March 18, 2025 at 06:55 am EDT - Marketscreener.com
ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ® - GlobeNewswire
Jefferies Initiates Coverage of ANI Pharmaceuticals (ANIP) with Buy Recommendation - Nasdaq
Ani Pharmaceuticals sr. VP Cook sells $25,332 in stock - Investing.com India
Ani Pharmaceuticals sr. VP Cook sells $25,332 in stock By Investing.com - Investing.com South Africa
Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts - Benzinga
ANI Pharma rises on expanded US approval for eye-disease drug - TradingView
ANI Pharmaceuticals Says FDA Approves Expanded Label for Iluvien -March 14, 2025 at 07:23 am EDT - Marketscreener.com
Jefferies Initiates Coverage on ANI Pharmaceuticals With Buy Rating, $80 Price Target - Marketscreener.com
ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label - GlobeNewswire
ILUVIEN Scores Major FDA Win: Now Treats Two Serious Eye Conditions - StockTitan
JPMorgan Chase & Co. Begins Coverage on ANI Pharmaceuticals (NASDAQ:ANIP) - Defense World
ANI Pharma wins Overweight rating at J.P. Morgan on growth prospects - MSN
ANI Pharma stock wins J.P. Morgan bullish view (ANIP:NASDAQ) - Seeking Alpha
Exploring Growth Opportunities: Raytheon, ANI Pharmaceuticals, DeckersNews and Statistics - IndexBox, Inc.
Zacks.com featured highlights include ANI Pharmaceuticals, Dana, Pitney Bowes, Priority Technology and Kingstone - Yahoo Finance
JPMorgan Initiates ANI Pharmaceuticals at Overweight With $85 Price Target -March 12, 2025 at 07:10 am EDT - Marketscreener.com
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Recommendation of “Buy” by Analysts - Defense World
ANI Pharmaceuticals at Leerink Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
ANI Pharmaceuticals Discusses Alimera Acquisition Challenges - TipRanks
Ani Pharmaceuticals’ chief HR officer Krista Davis sells $60,860 in stock - Investing.com Canada
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2024 Earnings Call Transcript - MSN
Don't Ignore The Insider Selling In ANI Pharmaceuticals - Simply Wall St
Top Executive at ANI Pharmaceuticals Sells Thousands in Stock! - TipRanks
Ani Pharmaceuticals SVP sells $323,049 in stock By Investing.com - Investing.com UK
ANI Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis - MarketBeat
Q1 Earnings Estimate for ANIP Issued By HC Wainwright - Defense World
ANI Pharma at Raymond James Conference: Strategic Shift to Rare Diseases - Investing.com Canada
Ani Pharmaceuticals’ Future Hinges on Ocumension’s Success with ILUVIEN in Asia-Pacific - MSN
Ani Pharmaceuticals Inc Stock (ANIP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):